Available online on http://www.ijhacr.com

International Journal of Health Advancement and Clinical Research (tz) 2024; 2(4); 29-33

Review Article

Nanosuspensions: A Paradigm Shift in Drug Delivery Systems

Dinesh Kumar Sain [1], Vijay Sharma [2], N Ravindra [3], Sunil Kumawat [4]

[1] Research Scholar, Goenka College of Pharmacy, Lachhmangarh, Sikar.
[2] Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.
[3] Principal and Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.
[4] Associate Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.

Received: 05-10-2024 / Revised: 07-11-2024 / Accepted: 06-12-2024
Corresponding author: Dinesh Kumar Sain
Conflict of interest: Nil

Abstract:

Nanosuspensions have emerged as a revolutionary drug delivery system, particularly effective in addressing the challenges associated with poorly water-soluble drugs. These colloidal dispersions, composed of nanosized drug particles stabilized by surfactants or polymers, significantly enhance solubility, dissolution rates, and bioavailability. They are versatile in their application, with suitability for oral, parenteral, ocular, pulmonary, and dermal routes of administration. This review discusses the types of nanosuspensions, methods for their evaluation, challenges faced during development and scale-up, and potential future advancements in the field. With the continuous evolution of nanotechnology, nanosuspensions offer a promising avenue for improving therapeutic outcomes and expanding the scope of pharmaceutical innovation.

Keywords: Nanosuspensions, poorly water-soluble drugs, colloidal dispersions, nanotechnology, surfactants.

Introduction

The pharmaceutical industry faces persistent challenges in formulating poorly water-soluble drugs, which comprise over 40% of newly discovered chemical entities. Traditional formulation strategies, such as salt formation, micronization, and cosolvency, often fall short of achieving desired solubility and bioavailability. Nanotechnology provides a novel solution through nanosuspensions, defined as sub-micron colloidal dispersions of drug particles stabilized using surfactants or polymers [1]. By reducing particle size to the nanometer scale, nanosuspensions increase surface area, enhance dissolution rates, and improve drug absorption. These systems are particularly advantageous for hydrophobic drugs, offering applications across diverse therapeutic areas. This review explores the fundamentals of nanosuspensions, their types, evaluation parameters, challenges, and future directions. [2]

Types of Nanosuspensions

Nanosuspensions can be broadly classified based on their formulation techniques and stabilizers employed:

Conventional Nanosuspensions:

Prepared using mechanical methods such as media milling and high-pressure homogenization.

Suitable for large-scale production with high stability and reproducibility.

Controlled-Release Nanosuspensions:

Formulated using modified stabilizers or encapsulation techniques to achieve

sustained drug release.

Ideal for chronic conditions requiring prolonged therapeutic effects.

Targeted Nanosuspensions:

Surface-modified with ligands, antibodies, or polymers to deliver drugs to specific tissues or cells.

Particularly beneficial for cancer therapy and site-specific treatments. [3]

Hybrid Nanosuspensions:

Combine conventional methods with advanced nanotechnology, such as Nanoedge or nanoprecipitation-homogenization techniques.

Offer better control over particle size and stability. [4]

Evaluation of Nanosuspensions

Nanosuspensions are colloidal dispersions of nanometer-sized drug particles stabilized by surfactants or polymers. Evaluating nanosuspensions involves assessing various physicochemical and biopharmaceutical parameters to ensure their efficacy, stability, and safety. Below are detailed explanations of the key evaluation parameters:

Particle Size and Size Distribution

The particle size of a nanosuspension significantly influences its dissolution rate, bioavailability, and stability. Particle size analysis, typically conducted using techniques such as dynamic light scattering (DLS) or laser diffraction, provides information about the mean particle size and the polydispersity index (PDI). A low PDI (<0.3) indicates a uniform particle size distribution, which is essential for consistent drug release and stability. Smaller particles with a narrow size distribution enhance the surface area, improving solubility and absorption.

Zeta Potential

Zeta potential measures the surface charge of particles in a nanosuspension and is a critical parameter for assessing stability. It reflects the degree of electrostatic repulsion between particles; higher absolute values (±30 mV or greater) indicate greater stability due to reduced particle aggregation. Zeta potential is measured using electrophoretic light scattering. Optimizing this parameter is essential to minimize particle aggregation and maintain a stable formulation over time. [5]

Drug Content and Encapsulation Efficiency

Drug content analysis determines the amount of active pharmaceutical ingredient (API) present in the nanosuspension, while encapsulation efficiency evaluates the percentage of drug successfully incorporated into the nanoparticles. These parameters are crucial for ensuring therapeutic efficacy. Techniques such as UV-visible spectroscopy, high-performance liquid chromatography (HPLC), or mass spectrometry are employed for this purpose. High encapsulation efficiency reflects effective formulation techniques and minimizes drug loss.

Crystallinity and Polymorphic Stability

The crystalline or amorphous nature of drug particles in a nanosuspension influences drug solubility and dissolution rate. Differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FTIR) are commonly used to analyze crystallinity. Changes in polymorphic form or crystallinity during formulation or storage can affect the drug's stability and bioavailability, making it essential to evaluate and control this parameter. [6]

Dissolution Rate and Solubility

Nanosuspensions are designed to improve the dissolution rate and solubility of poorly water-soluble drugs. In vitro dissolution testing, conducted using methods like the USP dissolution apparatus, helps measure the drug release profile over time. Faster

dissolution rates, attributable to the reduced particle size and increased surface area, lead to enhanced bioavailability. This parameter is vital for predicting in vivo drug performance.

Stability Studies

Stability is a critical parameter to evaluate the shelf-life of nanosuspensions. Stability studies involve assessing physical, chemical, and microbiological stability under different storage conditions (e.g., temperature, humidity, light). Parameters like particle size, zeta potential, drug content, and phase separation are monitored over time to ensure the formulation remains effective and safe. Accelerated stability studies help predict long-term behavior. [7]

pH and Osmolality

The pH of a nanosuspension must be within an acceptable range to ensure drug stability and compatibility with the intended route of administration (e.g., oral, parenteral). Deviations in pH can cause drug degradation or precipitation. Osmolality, especially for parenteral formulations, is evaluated to ensure isotonicity, minimizing irritation or adverse reactions upon administration.

Viscosity

Viscosity is an essential parameter, particularly for formulations intended for oral or parenteral administration. It affects the ease of handling, syringeability, and drug release profile. Rheological studies using a viscometer or rheometer help optimize the viscosity of nanosuspensions to achieve desired flow properties and stability. [8,9]

***In Vivo* Bioavailability**

In vivo studies assess the pharmacokinetics of nanosuspensions, such as absorption, distribution, metabolism, and excretion (ADME). Improved bioavailability, achieved through enhanced solubility and prolonged retention time, is the ultimate goal of nanosuspension formulations. Animal models or clinical trials help determine the therapeutic performance and safety of the formulation.

Surface Morphology

Surface morphology of particles is evaluated using techniques like scanning electron microscopy (SEM) or transmission electron microscopy (TEM). These techniques provide insights into particle shape, surface texture, and aggregation tendencies. Smooth and spherical particles often exhibit better stability and dissolution profiles compared to irregular or aggregated particles.

Redispersibility

For nanosuspensions stored as dry powders (e.g., after lyophilization or spray drying), redispersibility tests ensure the particles can be uniformly resuspended without significant changes in size or properties. This parameter is critical for maintaining consistency between the stored product and the administered suspension. [10,11]

Challenges in Nanosuspension Development

Despite their advantages, nanosuspensions face several challenges:

Stability Issues:

Particle aggregation, sedimentation, and Ostwald ripening can compromise the suspension's integrity.

Energy-Intensive Preparation:

Techniques like high-pressure homogenization require sophisticated equipment and high energy input. [12]

Scale-Up Complexity:

Maintaining uniform particle size and stability during large-scale production is challenging and resource-intensive. [13]

Formulation-Specific Requirements:

Selection of stabilizers and optimization of preparation methods must be tailored for each drug, increasing development time and costs.

Residual Solvent and Contamination:

Precipitation methods may leave residual solvents, while media milling risks contamination from milling beads.

Future Aspects

The field of nanosuspensions is rapidly evolving, with ongoing research focused on overcoming existing challenges and expanding applications:

Advanced Stabilization Techniques:

Development of novel surfactants and polymers to enhance stability and prevent aggregation.

Hybrid Preparation Methods:

Combining multiple techniques, such as Nanoedge technology, to improve scalability and reproducibility. [14]

Personalized Medicine:

Leveraging nanosuspensions for tailored drug delivery systems, particularly in oncology and precision therapy.

Integration with Emerging Technologies:

Combining nanosuspensions with 3D printing and microfluidics to design next-generation drug delivery systems.

Regulatory Advances:

Establishing standardized guidelines for the development, evaluation, and approval of nanosuspension-based formulations.

Green Nanotechnology:

Adoption of eco-friendly solvents and energy-efficient methods to reduce environmental impact during production. [15]

Conclusion

Nanosuspensions offer a versatile and effective solution to the challenges posed by poorly water-soluble drugs. Their ability to enhance solubility, bioavailability, and therapeutic efficacy makes them a vital tool in pharmaceutical sciences. While challenges related to stability, scalability, and formulation remain, advances in nanotechnology and preparation techniques are paving the way for their broader adoption. The future of nanosuspensions lies in their integration with personalized medicine and green nanotechnology, promising a new era of safe, efficient, and targeted drug delivery systems. Through continued innovation, nanosuspensions have the potential to revolutionize the treatment of a wide range of diseases, improving patient outcomes and expanding therapeutic possibilities.

References

1. E.M. Merisko-Liversidge, G.G. Liversidge. Drug nanoparticles: Formulating poorly watersoluble compounds. Toxicologic Pathology, 2008; 36:43-48.
2. Nagaraju P, Krishnachaithanya K, Srinivas VD, Padma SV. Nanosuspensions: A promising drug delivery system. Int J Pharm Sci Nano. 2010; 2:679–84.
3. Grau MJ, Kayser O, Muller RH. Nanosuspensions of poorly soluble drugs reproducibility of small-scale production. Int J Pharm. 2000; 196:155–7.
4. Patravale VB, Date AA, Kulkarni RM. Nanosuspension: A promising drug delivery strategy. J Pharm Pharmacol. 2004; 56:827–40.
5. Lakshmi P, Kumar GA. Nanosuspension technology: A review. Int J Pharm Pharm Sci. 2010; 2(4):35-40.
6. Geetha G, Poojitha U, Khan KA. Various techniques for preparation of nanosuspension-a review. International Journal of Pharma Research & Review. 2014; 3(9):30-7.
7. Kassem MA, Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. International journal of pharmaceutics. 2007; 340(1-2):126-33.

8. Yadav GV, Singh SR. Nanosuspension: A promising drug delivery system. Pharmacophore. 2012;3(5-2012):217-43.
9. Kumar Singh S, Vaidya Y, Gulati M, Bhattacharya S, Garg V, Kumar Pandey N. Nanosuspension: principles, perspectives and practices. Current drug delivery. 2016; 13(8):1222-46.
10. Dolenc A, Kristl J, Baumgartner S, Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. International journal of pharmaceutics. 2009; 376(1-2):204-12.
11. Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. International Journal of Pharmaceutics. 2011; 404(1-2):231-7.
12. Teeranachaideekul V, Junyaprasert VB, Souto EB, Müller RH. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. International journal of pharmaceutics. 2008; 354(1-2):227-34.
13. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. Journal of pharmacy and pharmacology. 2004; 56(7):827-40.
14. Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension. International journal of pharmaceutics. 2015; 478(2):540-52.
15. Ali HS, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. International journal of pharmaceutics. 2009; 375(1-2):107-13.